However, the potential contribution of CCT3 to Sorafenib resistance in HCC remains uncertain, although it has been observed to induce cisplatin resistance in lung adenocarcinomas through its targeting of JAK2/STAT3 [17]. The gene discussed is CCT3; the disease is hepatocellular carcinoma.